Adjuvant Pembrolizumab Does Not Affect Long-Term HRQOL in Stage III Melanoma
Source: OncLive , August 2024
Adjuvant pembrolizumab did not have a significant impact on long-term HRQOL outcomes in patients with resected stage III melanoma.
Treatment with pembrolizumab (Keytruda) in the adjuvant setting did not have a significant impact on long-term health-related quality of life (HRQOL) outcomes vs treatment with placebo in patients with resected stage III melanoma, supporting the utility of pembrolizumab in the adjuvant setting, according to data from the phase 3 EORTC 1325-MG/KEYNOTE-054 trial (NCT02362594) published in The Lancet Oncology.
At a clinical data cutoff date of January 17, 2022, a total of 514 patients were treated with pembrolizumab, and 505 were treated with placebo; completion of the HRQOL evaluation at baseline was 94% in the pembrolizumab group and 92% in the placebo group. From baseline, the mean change in long-term global health status/quality of life scale (GHQ) was –0.56 (95% CI, –2.33-1.22) and 1.63 (95% CI, –0.12-3.38) in the pembrolizumab and placebo arms, respectively. This led to a difference of –2.19 (95% CI, –4.65-0.27; P = .081) between the 2 groups, though all other scales were not statistically significant.